A practical reference on Angiotensin IV: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-14. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized research form. |
| Solubility | Soluble in DMSO; limited in water | Depends on purity and salt form. |
| Storage temperature | -20 °C or lower | Desiccated and protected from light. |
| Analytical method | RP-HPLC and LC-MS | Common for purity and identity. |
| Regulatory status | Research chemical in many countries | Not widely approved as a medicine. |
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Some authors use the quantity S/f as the sorptivity. The above description is for the case where gravity and evaporation do not play a role. Sorptivity is a relevant property of building materials, because it affects the amount of rising dampness. Some values for the sorptivity of building materials are in the table below.
=== Research === TRH has been evaluated for the treatment of various neurological disorders. It has been attempted for treatment of various epileptic disorders. TRH has been shown to improve outcomes of CNS injuries in experimental models. Efficacy for the treatment ALS and spinal muscle atrophy has not been demonstrated. Many individuals with depression exhibit a blunted endocrine response to TRH due to unknown reasons, and the response is correlated with clinical outcomes. Involvement of TRH in the pathogenesis of depression has nevertheless not been well established. TRH has undergone research for its ostensible antidepressant properties, however, results regarding efficacy have been inconsistent. One study on a small sample of people with treatment-resistant depression found short-lived anti-depressant and anti-suicidal effects when TRH was administered intrathecally. An orally bioavailable prodrug is being researched. In 2012, the U.S. Army awarded a research grant to develop a TRH nasal spray for suicide prevention amongst veterans. TRH acts as a wakefulness-promoting agent, causing awakening from sleep or sedation.
A cancer-associated fibroblast (CAF) (also known as tumour-associated fibroblast; carcinogenic-associated fibroblast; activated fibroblast) is a cell type within the tumor microenvironment that promotes tumorigenic features by initiating the remodelling of the extracellular matrix or by secreting cytokines. CAFs are a complex and abundant cell type within the tumour microenvironment; the number cannot decrease, as they are unable to undergo apoptosis. CAFs have been found to be abundant in a tumour stroma. Myofibroblasts and fibroblasts make up CAFs. The functions of these CAFs have been known to stimulate angiogenesis, supporting the formation of tumours and thus proliferation of cancer cell and metastasis. Cancer cells are usually also drug resistant, which is contributed by CAFs. As such, this interaction is being studied for potential anti-cancer therapy. Normal fibroblasts aid in the production of components of the extracellular matrix such as collagens, fibres, glycosaminoglycans and glycoproteins and are therefore vital in tissue repair in wound healing. CAFs however, are derived from either normal fibroblasts, pericytes, smooth muscle cells, fibrocytes or mesenchymal stem cells These CAFs then go on to support tumour growth by secreting growth factors such as Vascular Endothelial Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF) and Fibroblast Growth Factor (FGF) and other chemokines to stimulate angiogenesis and thus the growth of a tumour.
== Types == In mammals, NADPH oxidase is found in two types: one in white blood cells (neutrophilic) and the other in vascular cells, differing in biochemical structure and functions. Neutrophilic NADPH oxidase produces superoxide almost instantaneously, whereas the vascular enzyme produces superoxide in minutes to hours. Moreover, in white blood cells, superoxide has been found to transfer electrons across the membrane to extracellular oxygen, while in vascular cells, the radical anion appears to be released mainly intracellularly.
=== Covalent peptide tags === Isopeptag, a peptide which binds covalently to pilin-C protein (TDKDMTITFTNKKDAE) SpyTag, a peptide which binds covalently to SpyCatcher protein (AHIVMVDAYKPTK) SnoopTag, a peptide which binds covalently to SnoopCatcher protein (KLGDIEFIKVNK). A second generation, SnoopTagJr, was also developed to bind to either SnoopCatcher or DogTag (mediated by SnoopLigase) (KLGSIEFIKVNK) DogTag, a peptide which covalently binds to DogCatcher (DIPATYEFTDGKHYITNEPIPPK) and can react as an internal tag in loops of proteins. DogTag can also covalently bind to SnoopTagJr, mediated by SnoopLigase. SdyTag, a peptide which binds covalently to SdyCatcher protein (DPIVMIDNDKPIT). SdyTag/SdyCatcher has a kinetic-dependent cross-reactivity with SpyTag/SpyCatcher.
Sources: en.wikipedia.org
== Personal life == In 1963, Horváth married Valeria Scioscioli in Rome, and they emigrated to the United States. He joined the Physics Research Laboratory at Harvard Medical School. The couple had two daughters.
== External links == Laws, ordinances, guidelines, expert opinions and publications on radiation protection Archived 2018-03-18 at the Wayback Machine, timeline since 2002 of the Federal Ministry for the Environment, Nature Conservation, Nuclear Safety and Consumer Protection. Retrieved on November 28, 2017. Guidelines for quality assurance in radiology Archived 2013-07-15 at the Wayback Machine (PDF) German Medical Association, November 23, 2007. Retrieved December 4, 2017. DIN Radiology Standards Archived 2013-07-15 at the Wayback Machine (PDF) DIN Radiology Standards Committee NAR in cooperation with the German Radiological Society, June 2015, accessed December 4, 2017. Radiation protection in veterinary medicine - Guideline to the Radiation Protection Ordinance (StrlSchV) and the X-ray Ordinance (RöV) (PDF) September 25, 2014, Federal Ministry for the Environment, Nature Conservation, Building and Nuclear Safety, Division Medical-Biological Affairs of Radiation Protection Ref. RS II 4 - 11432/7. Retrieved November 28, 2017. Radioactivity and radiation protection (PDF; 6.6 MB) Federal Office of Public Health (Switzerland), July 2007, accessed November 25, 2017. Overview of international radiation protection associations and organizations, Austrian Association for Radiation Protection. Retrieved December 3, 2017. Human Radiation Experiments DOE Openness. Retrieved January 10, 2018. Department of Energy OpenNet Resources. Retrieved January 10, 2018. Igor Gusev, Angelina Guskova, Fred A. Mettler: Medical Management of Radiation Accidents, Second Edition.
=== Drug engineering === By identifying the antigens responsible for a particular immune response, it is possible to identify viable targets for novel drugs. In addition, specific antigens can further be classified based on immunoreactivity for identification of future potential vaccine preparations. In addition to the identification of vaccine candidates, immunoproteomic techniques such as western blotting can additionally be used for measuring the efficacy of a given vaccine.
Following Alice in Chains' extensive 1993 world tour, Staley said the band "just wanted to go into the studio for a few days with our acoustic guitars and see what happened." "We never really planned on the music we made at that time to be released. But the record label heard it and they really liked it. For us, it was just the experience of four guys getting together in the studio and making some music." Columbia Records released Alice in Chains' second acoustic-based EP, Jar of Flies, on January 25, 1994. Written and recorded in one week, Jar of Flies debuted at number one on the Billboard 200, becoming the first EP—and first Alice in Chains release—to top the charts. Paul Evans of Rolling Stone called the EP "darkly gorgeous", and Steve Huey said, "'Jar of Flies' is a low-key stunner, achingly gorgeous and harrowingly sorrowful all at once." Jar of Flies features Alice in Chains' first number-one single on the Mainstream Rock charts, "No Excuses". The second single, "I Stay Away", reached number ten on the Mainstream rock charts, while the final single "Don't Follow", reached number 25. Jar of Flies has been certified triple platinum by the RIAA, with over 2 million copies sold in the United States during its first year. Jar of Flies received two Grammy nominations, Best Hard Rock Performance for "I Stay Away", and Best Recording Package. After the release of Jar of Flies, Staley entered rehab for heroin addiction.
== Production == The method of freeze-drying is used for production. The liquid of the bean curd turns into ice. Freezing changes the color, texture, size, and weight, after which it is thawed. At the end of the process, a beige and sponge-like tofu essence are achieved.
Sources: en.wikipedia.org
This suggested that it was evolutionarily more difficult to increase the UV-sensitivity of the eyes of the males than to increase the UV-signals emitted by the females. Many insects use the ultraviolet wavelength emissions from celestial objects as references for flight navigation. A local ultraviolet emitter will normally disrupt the navigation process and will eventually attract the flying insect.
In the prairie vole, oxytocin released into the brain of the female during sexual activity is important for forming a pair bond with her sexual partner. Vasopressin appears to have a similar effect in males. Oxytocin has a role in social behaviors in many species, so it likely also does in humans. In a 2003 study, both humans' and dogs' oxytocin levels in the blood rose after a five to 24-minute petting session. This possibly plays a role in the emotional bonding between humans and dogs.
Some Australian cities (such as Sydney) have instituted legal diamorphine supervised injecting centers, in line with other wider harm minimization programs. Since January 2009, Denmark has prescribed diamorphine to a few addicts who have tried methadone and buprenorphine without success. Beginning in February 2010, addicts in Copenhagen and Odense became eligible to receive free diamorphine. Later in 2010, other cities including Århus and Esbjerg joined the scheme. It was estimated that around 230 addicts would be able to receive free diamorphine. However, Danish addicts would only be able to inject heroin according to the policy set by Danish National Board of Health. Of the estimated 1500 drug users who did not benefit from the then-current oral substitution treatment, approximately 900 would not be in the target group for treatment with injectable diamorphine, either because of "massive multiple drug abuse of non-opioids" or "not wanting treatment with injectable diamorphine". In July 2009, the German Bundestag passed a law allowing diamorphine prescription as a standard treatment for addicts; a large-scale trial of diamorphine prescription had been authorized in the country in 2002. On 26 August 2016, Health Canada issued regulations amending prior regulations it had issued under the Controlled Drugs and Substances Act; the "New Classes of Practitioners Regulations", the "Narcotic Control Regulations", and the "Food and Drug Regulations", to allow doctors to prescribe diamorphine to people who have a severe opioid addiction who have not responded to other treatments.
=== Purification === Due to the challenging chemical synthesis of the neurotoxin, most studies were conducted using a purified form. To investigate the effects of the α-bungarotoxin, the toxin has to be isolated from the venom of the elapid snake. The purification of the polypeptide is done via column chromatography. Firstly, the venom is dissolved in ammonium acetate buffer and then loaded on the CM-Sephadex column. The elution of the compound is done in two different steps by using an ammonium acetate buffer at a flow rate of 35 nl/h. The steps involve using two linear gradients of buffers while increasing the pH.
Sources: en.wikipedia.org
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.
Mass spectrometry is commonly used to confirm molecular mass, while RP-HPLC estimates purity. These methods can be combined with amino acid analysis or NMR for further structural confirmation. A certificate of analysis alone does not guarantee independent verification.
Legality depends on the country and the intended use. In many places it is not approved as a drug and may be regulated as a research chemical. Buyers should check local laws and institutional policies before obtaining it.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.